Articles


http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01087-9/abstract


When the Supreme Court meets next week to hear its first abortion-related case in nearly a decade, the justices will consider the most significant challenge to an argument that has become central to the antiabortion cause: that abortion hurts not just a fetus but also its mother. Continue reading…
“Oklahoma Supreme Court upholds state law on limiting abortion drugs,” Jon Herskovitz, Reuters, February 23, 2016.

The Oklahoma Supreme Court on Tuesday upheld a law aimed at limiting the use of abortion-inducing drugs, overturning a lower court decision that said the measure was unconstitutional because it did not apply to other medication. Continue reading…


Today in the United States, conservative social mores are putting women’s access to safe and affordable contraception at risk. Even in 2016, there is no assurance that birth control will be accessible to all U.S. women regardless of ability to pay. The author situates the present debate in the context of the legal debate of the past fifty years. Continue reading…


Despite 30 years of advocacy, the prevalence of non-therapeutic female genital alteration (FGA) in minors is stable in many countries. Educational efforts have minimally changed the prevalence of this procedure in regions where it has been widely practiced. In order to better protect female children from the serious and long-term harms of some types of non-therapeutic FGA, the authors argue that we must adopt a more nuanced position that acknowledges a wide spectrum of procedures that alter female genitalia. Continue reading…


Re-consent in research, the asking for a new consent if there is a change in protocol or to confirm the expectations of
participants in case of change, is an under-explored issue. There is little clarity as to what changes should trigger re-consent and what impact a re-consent exercise has on participants and the research project. This article examines applicable policy statements and literature for the prevailing arguments for and against re-consent in relation to longitudinal cohort studies, tissue banks and biobanks. Continue reading…


Large-scale biobanks represents an important scientific and medical as well as a commercial opportunity. However, realizing these and other prospects requires social, legal, and regulatory conducive climate, as well as a capable scientific community and adequate infrastructure, Israel has been grappling with the appropriate approach to establishing such a repository, and debates over the governance, structure, finance, and mode of operation shed a bright light on the underlying social norms, civic engagement and scientific clout in steering a governmental response to pressing medical needs. The article presents the backdrop of the Israeli scene, and explores the reasons and forces at work behind the current formulation of the Israeli National Biobank, MIDGAM. Continue reading…


http://nyti.ms/1TCC1mE

http://nyti.ms/1TxbtTH

http://nyti.ms/1TzLwmA

http://nyti.ms/1TzIBu5

http://nyti.ms/1RovJF1

http://nyti.ms/1TAruIB

http://nyti.ms/1TywBZZ

“How Animal Testing and Research is Advancing Treatments for Type 2 Diabetes,” Foundation for Biomedical Research, March 2016
http://fbresearch.org/how-animal-testing-and-research-is-advancing-treatments-for-type-2-diabetes/


“All Surrogacy is Exploitation – the world should follow Sweden’s ban,” Kajsa Ekis Ekman, The Guardian, February 25, 2016
http://www.theguardian.com/commentisfree/2016/feb/25/surrogacy-sweden-ban

http://nyti.ms/1TwCff8

“A Million Times More Harmful Than Outdoor Air: Hong Kong Study Raises W-Cigarette Cancer Alarm, Elizabeth Cheung, South China Morning Post, February 29, 2016


http://nyti.ms/1Qop23D
http://nyti.ms/1RAUPkg

http://nyti.ms/1LpQCR8

http://nyti.ms/1TJYm1C

http://nyti.ms/1RKCVvj